Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the …
FE Lecouvet, DE Oprea-Lager, Y Liu, P Ost… - The Lancet …, 2018 - thelancet.com
Oligometastatic disease represents a clinical and anatomical manifestation between
localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition …
localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition …
Oligometastatic prostate cancer: reality or figment of imagination?
CC Foster, RR Weichselbaum, SP Pitroda - Cancer, 2019 - Wiley Online Library
The term “oligometastatic prostate cancer” refers to a heterogeneous group of disease states
currently defined solely on the basis of clinical features. Oligorecurrent disease, de novo …
currently defined solely on the basis of clinical features. Oligorecurrent disease, de novo …
Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial
Background Stereotactic ablative body radiotherapy (SABR) is an emerging treatment option
for oligometastatic prostate cancer. However, limited prospective evidence is available …
for oligometastatic prostate cancer. However, limited prospective evidence is available …
[HTML][HTML] Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus
Background and purpose Oligometastatic prostate cancer is a new and emerging treatment
field with only few prospective randomized studies published so far. Despite the lack of …
field with only few prospective randomized studies published so far. Despite the lack of …
Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body …
Background Stereotactic body radiotherapy (SBRT) and elective nodal radiotherapy (ENRT)
are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer …
are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer …
OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in …
Background Oligorecurrent pelvic nodal relapse in prostatic cancer is a challenge for
regional salvage treatments. Androgen depriving therapies (ADTs) are a mainstay in …
regional salvage treatments. Androgen depriving therapies (ADTs) are a mainstay in …
68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment …
Purpose The primary aim of this retrospective, single-centre analysis was to assess the
performance of 68 Ga-PSMA-11 PET/CT in prostate cancer (PCa) patients in early PSA …
performance of 68 Ga-PSMA-11 PET/CT in prostate cancer (PCa) patients in early PSA …
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
L Triggiani, F Alongi, M Buglione, B Detti… - British journal of …, 2017 - nature.com
Background: The aim of the present study is to evaluate the impact of metastases-directed
stereotactic body radiotherapy in two groups of oligometastatic prostate cancer (PC) …
stereotactic body radiotherapy in two groups of oligometastatic prostate cancer (PC) …
PEACE V–Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): A study protocol for a randomized controlled phase II trial
A De Bruycker, A Spiessens, P Dirix, N Koutsouvelis… - BMC cancer, 2020 - Springer
Background Pelvic nodal recurrences are being increasingly diagnosed with the
introduction of new molecular imaging techniques, like choline and PSMA PET-CT, in the …
introduction of new molecular imaging techniques, like choline and PSMA PET-CT, in the …
Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case …
T Steuber, C Jilg, P Tennstedt, A De Bruycker… - European urology …, 2019 - Elsevier
Abstract Background Most prostate cancer (PCa) patients with a biochemical failure
following primary multimodality treatment (surgery and postoperative radiotherapy) relapse …
following primary multimodality treatment (surgery and postoperative radiotherapy) relapse …